Atara Biotherapeutics Inc (ATRA)
Atara Biotherapeutics is engaged in T-cell immunotherapy, using its allogeneic Epstein-Barr virus (EBV) T-cell platform to develop therapies for patients with diseases, including tumors, hematologic cancers and autoimmune disease. Co.'s platform utilizes the biology of EBV T cells and has the capability to treat a range of EBV-driven diseases or other diseases through incorporation of engineered chimeric antigen receptors or T-cell receptors. Co.'s T-cell immunotherapy program, tab-cel® (tabelecleucel), is partnered with Pierre Fabre Medicament and is in Phase 3 development for patients with EBV-driven post-transplant lymphoproliferative disease.
ATRA SEC Filing Email Alerts Service
| Company Name: |
Atara Biotherapeutics Inc |
| Website: |
www.atarabio.com |
| Sector: |
Biotechnology |
| Number of ETFs Holding ATRA: |
15 |
| Total Market Value Held by ETFs: |
$5.63M |
| Total Market Capitalization: |
$73.00M |
| % of Market Cap. Held by ETFs: |
7.72% |
|
|
April 26, 2024 • 1:43 AM Eastern
Hold (2.00 out of 4)
0th percentile
|
|
Free ATRA Email Alerts:
